Author of

• 17783

  +

  P2.05 - Poster Session with Presenters Present (ID 463)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Radiotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17791

    +

    P2.05-008 - Can Stereotactic Body Radiation Therapy (SBRT) Be an Effective Treatment for Lung Metastases From "Radioresistant" Histologies? (ID 4419)

    14:30 - 14:30  |  Author(s): G.R. D'Agostino
    • Abstract

    Background:
    Metastasis from “radioresistant” histologies are commonly regarded as less responsive to SBRT. Almost no data are available in Literature to evaluate the impact of these histologies on the outcome of patients with lung metastases treated with Stereotactic Body Radiation Therapy (SBRT). Therefore, we conducted this analysis on patients with lung metastases from renal cell carcinoma, hepatocellular carcinoma, adenoid cystic carcinoma and melanoma treated with SBRT in our Institution.
    
    Methods:
    Oligometastatic patients with lung metastases from renal cell carcinoma, hepatocellular carcinoma, adenoid cystic carcinoma and melanoma who received SBRT and with a discrete follow up time were included in this analysis. Kaplan Meyer analysis was used to calculate Overall Survival, Progression Free Survival, Local Control. Crude rates were used to calculate the response and distant failure rates. Toxicity was scored according to CTCAE v. 4.03
    
    Results:
    Sixty patients were included in the study. Most common primary histologies were renal cell carcinoma and hepatocellular carcinoma. Most of patients had 1 or 2 metastatic sites. Half patents did not receive any systemic therapy during their history before SBRT. Different RT doses and number of fractions were utilized according to site, number and volume of lung metastases, 48 Gy in 4 fractions was the most commonly prescribed schedule. The best local responses obtained were complete response in 13 patients (21.7%), partial response in 28 patients (46.7%) and stable disease in 14 patients (23.3%). Five patients (8.3%) had a local progression. With a median follow up of 24.3 months (range 4.1-118.6 months), local control was 93.7% and 86.1% at 1 and 2 years respectively. OS and PFS at 1 and 2 year were 89.5%, 64.6%, 87.7% and 70.1%, respectively. None of the analyzed parameters showed a statistically significant impact on any outcome. Treatment was well tolerated. None but one patients experienced acute toxicity of any grade. During follow up in 10 cases G1-2 toxicity (mostly pneumonia) were recorded.
    
    Conclusion:
    SBRT for lung metastases is an effective treatment for oligometastatic patients with lung metastases from “radioresistant” histologies. The treatment is safe and well tolerated and the outcomes are equivalent to the results obtainable with SBRT for lung metastases from more favourable histologies.